EU updates EudraLex Q&A on requirements for drug/device trials
This article was originally published in SRA
The European Commission has issued an updated question & answer document on its guidance for pharmaceutical clinical trials (EudraLex Volume 10), explaining the implications of the current EU clinical trials legislation if the study also involves a medical device1,2.
You may also be interested in...
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.